February 17, 2014
Novartis Pharma may have drafted or updated the regulations of the Tokyo CML Conference (TCC) that initiated the “SIGN” clinical trial for Novartis’s chronic myeloid leukemia (CML) treatment Tasigna (nilotinib), according to sources. Sources told Jiho that the company name...read more